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Abstract
Background: Awareness of lung cancer screening remains low in the screening-eligible population, and when patients visit
their clinician never having heard of lung cancer screening, engaging in shared decision making to arrive at an informed decision
can be a challenge. Therefore, methods to effectively support both patients and clinicians to engage in these important discussions
are essential. To facilitate shared decision making about lung cancer screening, effective methods to prepare patients to have
these important discussions with their clinician are needed.
Objective: Our objective is to develop a computer-tailored decision support tool that meets the certification criteria of the
International Patient Decision Aid Standards instrument version 4.0 that will support shared decision making in lung cancer
screening decisions.
Methods: Using a 3-phase process, we will develop and test a prototype of a computer-tailored decision support tool in a sample
of lung cancer screening-eligible individuals. In phase I, we assembled a community advisory board comprising 10 screening-eligible
individuals to develop the prototype. In phase II, we recruited a sample of 13 screening-eligible individuals to test the prototype
for usability, acceptability, and satisfaction. In phase III, we are conducting a pilot randomized controlled trial (RCT) with 60
screening-eligible participants who have never been screened for lung cancer. Outcomes tested include lung cancer and screening
knowledge, lung cancer screening health beliefs (perceived risk, perceived benefits, perceived barriers, and self-efficacy), perception
of being prepared to engage in a patient-clinician discussion about lung cancer screening, occurrence of a patient-clinician
discussion about lung cancer screening, and stage of adoption for lung cancer screening.
Results: Phases I and II are complete. Phase III is underway. As of July 15, 2017, 60 participants have been enrolled into the
study, and have completed the baseline survey, intervention, and first follow-up survey. We expect to have results by December
31, 2017 and to have data analysis completed by March 1, 2018.
Conclusions: Results from usability testing indicate that the computer-tailored decision support tool is easy to use, is helpful,
and provides a satisfactory experience for the user. At the conclusion of phase III (pilot RCT), we will have preliminary effect
sizes to inform a future fully powered RCT on changes in (1) knowledge about lung cancer and screening, (2) perceived risk of
lung cancer, (3) perceived benefits of lung cancer screening, (4) perceived barriers to lung cancer screening, (5) self-efficacy for
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lung cancer screening, and (6) perceptions of being adequately prepared to engage in a discussion with their clinician about lung
cancer screening.
(JMIR Res Protoc 2017;6(11):e225)   doi:10.2196/resprot.8694
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Introduction
Lung cancer screening is a US Preventive Services Task Force
(USPSTF) grade B recommendation, indicating there is high
certainty that the overall benefits are substantial [1]. The
National Lung Screening Trial, on which the recommendation
is based, found a 20% lung cancer-related mortality reduction
for long-term smokers screened annually with low-dose
computed tomography (LDCT) compared with chest radiography
[2]. However, lung cancer screening with LDCT is a complex
issue. Screening has associated risks and potential harms that
complicate the decision to screen [1]. Most notable among these
are false-positive results and incidental findings, which can lead
to a cascade of unnecessary invasive testing [1,2]. Therefore,
the USPSTF recommends that the decision to screen for lung
cancer should be the result of a shared decision-making process
between a patient and their clinician. In addition to shared
decision making being incorporated into the lung cancer
screening guideline [1], for the first time, it is a requirement for
reimbursement of a cancer screening test from Medicare [3].
Our team’s preliminary work revealed that most individuals
eligible for lung cancer screening are unaware of, or confused
or misinformed about (1) how lung cancer screening is
performed, (2) the benefits and associated risks of screening,
and (3) the causes of and associated risk factors for developing
lung cancer [4]. It is critical to increase long-term smokers’
awareness of and education about lung cancer and screening.
Education is an essential component of the shared
decision-making process, and the USPSTF guidelines provide
criteria for whom to engage in shared decision making about
lung cancer screening [1]. The screening decision should,
therefore, be the result of a clinical encounter in which the
clinician and patient engage in shared decision making. Patients
who are involved in decision making about their health have
better outcomes [5], and shared decision making is ideally suited
for the complex nature of the decision to screen, or not, for lung
cancer. However, awareness of lung cancer screening remains
low in the screening-eligible population [6]. In our team’s recent
study exploring the decision to opt in or out of lung cancer
screening, our findings highlighted the prevalence of
time-constrained clinical encounters and their negative effect
on the shared decision-making process about screening [7].
When a patient visits their clinician and has never heard of lung
cancer screening before, engaging in the shared decision-making
process to arrive at an informed decision can be a challenge.
Methods to effectively support both patients and clinicians to
engage in shared decision making are essential. Importantly, to
facilitate this process, effective methods to prepare patients to
have these important discussions with their clinician are needed.
Several decision aids [8-11] have been developed in response
to the USPSTF lung cancer screening guideline and Medicare
mandate for shared decision making. However, few are
theoretically grounded. To our knowledge, 2 theoretically
grounded lung cancer screening decision aids have been
published in the literature and both are conceptually framed
from a perspective of risk [8,9]. Volk and colleagues developed
the video Lung Cancer Screening: Is It Right for Me? [8]. This
6-minute video provides information about risk factors for lung
cancer, and harms and benefits of lung cancer screening, and
presents vignettes depicting trade-offs between harms and
benefits to clarify values [8]. Initial feasibility showed that this
decision aid increased knowledge (P<.01) and supported
readiness to make a decision to screen for lung cancer as
reflected in significantly higher values clarity scores [8]. Lau
and colleagues developed a Web-based decision aid guided by
the Ottawa Decision Support Framework using an established
prediction model to compute baseline lung cancer risk and an
individual’s chance of benefiting from, and risk of being harmed
by, screening [9]. Knowledge of lung cancer and screening
increased (P<.001) and decisional conflict decreased (P<.001)
in initial feasibility testing [9]. Other commercially developed
lung cancer screening decision aids focus on calculating personal
risk for the development of lung cancer with subsequent
screening recommendations based on the calculated risk [10,11].
As mentioned, lung cancer screening is a complex issue with
associated risks and potential harms that complicate the decision
to screen. During phase I with our community advisory board
(CAB; described in more detail below), participants expressed
concern about messaging for former smokers being similar to
that for current smokers and the potential for increased perceived
stigma. This highlighted the importance of tailoring a decision
support tool based on smoking status. With careful consideration
of the messaging, we chose a tailored approach because tailored
interventions are more effective than nontailored ones, and have
been shown to improve knowledge, change health beliefs, and
promote health behavior change in other types of cancer
screening such as breast and colorectal cancers [12-17]. Our
previous research revealed that perceived risk was not associated
with actual screening behavior in lung cancer [18]. Regardless,
it is important for any decision support tool in lung cancer
screening to include risks for the development of lung cancer;
however, to support the shared decision-making process in lung
cancer screening, it is critical that lung cancer screening decision
aids go beyond assessing risk and that they tailor messages
based on multiple salient variables that may be personally
relevant to the individual. Lung cancer screening decision aids
should also leverage the previsit time frame (ie, during either
the time spent waiting in the clinic before the clinician comes
in for the visit or the week leading up to a scheduled well-care
JMIR Res Protoc 2017 | vol. 6 | iss. 11 | e225 | p.2http://www.researchprotocols.org/2017/11/e225/
(page number not for citation purposes)
Carter-Harris et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
appointment, in which patient education can be consumed at
home) to prime patients with new knowledge about lung health
and the option of screening. Educating patients during the
previsit time period has the potential to enhance the subsequent
clinical encounter for patient engagement in a shared
decision-making process.
It is also important to acknowledge the role stigma may play in
lung cancer screening discussions and decisions. Individuals
qualify for lung cancer screening based on their history of
long-term tobacco use, and smokers are different from
populations targeted for other types of cancer screening, which
base eligibility on age and sex. Smokers have reported
perceiving blame and feeling stigmatized in clinical encounters
secondary to their status as a current or former smoker [4,19].
Further, initial focus group discussions with screening-eligible
individuals revealed that former smokers did not wish to be
addressed as a current smoker. Therefore, patient decision aids
for lung cancer screening may benefit from tailoring messages
and content by smoking status.
This paper discusses the development and usability testing of
a computer-tailored decision support tool called LungTalk. This
decision support tool was developed using the USPSTF lung
cancer screening guideline and the qualifying and certification
criteria of the International Patient Decision Aid Standards
instrument version 4.0 as a guide [20]. The purpose of LungTalk
is to prepare individuals for the shared decision-making process
about lung cancer screening by educating individuals about (1)
lung health broadly including the effects of nicotine, (2) risk
factors for the development of lung cancer, (3) the option of
lung cancer screening with LDCT of the chest, and (4) risks
and benefits of lung cancer screening. The content and messages
of LungTalk are tailored by smoking status. LungTalk is Web
based and can be delivered via email or sent to a patient via a
health system’s patient portal with an embedded weblink prior
to an upcoming clinic visit. LungTalk can also be delivered via
a tablet-based device in the clinic.
Methods
We developed a prototype of a computer-tailored decision
support tool using user-centered design based on the most recent
USPSTF lung cancer screening guidelines and the International
Patient Decision Aid Standards instrument version 4.0 checklist.
Its aim was to (1) educate individuals about lung health and
lung cancer screening, (2) prepare them to engage in a discussion
about screening with their clinician, and (3) enhance the shared
decision-making process between clinicians and
screening-eligible patients. This study was approved by the
Institutional Review Board at Indiana University prior to
recruitment, and we obtained informed consent prior to study
participation. We used a 3-phase process to develop and test
the prototype in the target population. We describe the process
below by phase.
Phase I: Development
Overview
The computer-tailored decision support tool was developed by
a team of researchers and clinicians with expertise in behavioral
science, nursing, primary care, oncology, lung cancer screening,
and informatics. Informed by a CAB comprising 10
screening-eligible individuals, the computer program was named
LungTalk because the program goes beyond educating
individuals solely about lung cancer screening to also educate
broadly about lung health. We designed LungTalk to increase
the users’ awareness of potential risks related to long-term
nicotine exposure, benefits of and potential harms related to
lung cancer screening, and importance of shared decision
making in the decision to screen for lung cancer or not, and to
prompt users to initiate a discussion with a clinician about lung
cancer screening.
LungTalk is unique in that it tailors messages based on smoking
status and provides a tailored printout to help patients initiate
a discussion with their clinician about their lung health and the
option of screening. Our prior qualitative research with
screening-eligible individuals revealed that many former
smokers perceived stigma in clinical encounters where their
long-term tobacco use was a focus [4,7]. This highlighted the
importance of considering the framing of messaging based on
smoking status in the development of the content of the decision
support tool, as well as the importance of providing support for
a discussion through a tailored printout.
Recruitment of Community Advisory Board Members
Our target population for LungTalk was lung cancer
screening-eligible individuals based on the USPSTF lung cancer
screening criteria [1]. These included persons who are aged 55
to 80 years, and current smokers or former smokers who had
quit within the past 15 years with a minimum 30-pack-year
tobacco smoking history [1]. We recruited CAB members from
the local community using newspaper advertisement and through
the Indiana University Health Lung Screening Clinic,
Indianapolis, Indiana, USA, to ensure equal representation of
individuals who had recently been screened for lung cancer and
individuals who had not been screened.
Development of LungTalk With the Community Advisory
Board
In phase I, we assembled the CAB to provide critical input and
feedback during the initial development of LungTalk. We held
3 CAB meetings over the course of 6 months under the direction
of 2 researchers (LCH and SMR) to discuss individual
components of the computer program. Guided by user-centered
design and in consultation with the study’s design team
(consisting of experts in informatics, user experience design
and engineering, and visual communication), we asked members
of the CAB to provide iterative feedback on the design and
prototypes, preferences for how the program should “look and
feel,” and expectations of how the program should work when
used in real-world settings. More specifically, the CAB provided
feedback on what should and should not be included;
development of, and specific wording for, messages to constitute
the content library for LungTalk; specific graphic components
of the program; and the tailored printout. Each CAB meeting
was audiotaped in order to accurately capture feedback from
CAB members and facilitate prototype revisions with the design
team. Digital audio recordings and field notes from the CAB
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meetings were reviewed by a researcher (LCH) and summarized
for the design team.
Description of LungTalk
LungTalk is a computer-tailored decision support tool that is
theoretically grounded in the conceptual model on lung cancer
screening participation [21]. This model links the health belief
model to the precaution adoption process model and includes
key psychological variables (eg, stigma, mistrust, fatalism, fear,
and worry) as factors that may influence an individual’s decision
to screen, or not, for lung cancer [21]. The LungTalk prototype
is an interactive program that includes audio, video, and
animation segments with tailoring algorithms for scripts
presented from the master content library. In addition, LungTalk
offers the option of saving or printing a tailored printout at the
end. This printout highlights key points related to lung health
and screening tailored by smoking status, offers question
prompts the user can use to initiate the discussion with their
clinician, and tailors messages based on questions that remain
important to the user that they wish to discuss further with their
clinician. Literacy level has been considered in the development
of LungTalk and messaging is presented at an eighth-grade
level. In addition, in consideration of different ways people like
to learn, the content is presented via narration as well as key
text on screen.
Phase II: Usability Testing
Overview
Following the initial prototype development of LungTalk, we
conducted usability testing with 13 screening-eligible individuals
(different from those constituting the CAB). Table 1 presents
the sociodemographic characteristics of the CAB and usability
testers.
Data Collection
Pretesting took place in the usability testing laboratory at the
Indiana University School of Informatics. We used the method
for iterative usability evaluation based on the Milano-Lugano
evaluation method systematic usability inspection technique
[22]. This method enabled us to identify communication
breakdowns and recommend design improvements on task
support, information architecture, navigation design, and
interaction mechanisms.
Table 1. Phase I and phase II participant sociodemographic and health status characteristics.
Usability testing (n=13)Community advisory board (n=10)Characteristics
62.6 (7.2)63.3 (6.7)Age (years), mean (SD)
Sex, n (%)
10 (77)6 (60)Male
3 (23)4 (40)Female
Race, n (%)
10 (77)4 (40)White
3 (23)6 (60)Black
Education, n (%)
1 (8)1 (10)Less than high school
0 (0)4 (40)High school graduate
7 (54)4 (40)Some college
5 (39)1 (10)College graduate or higher
Income (US $), n (%)
6 (46)2 (20)<25,000
2 (15)5 (50)25,000-50,000
5 (39)3 (30)>50,000
Health insurance, n (%)
5 (39)6 (60)Government
8 (62)4 (40)Private
Smoking status, n (%)
4 (31)5 (50)Current smoker
9 (69)5 (50)Former smoker
Family history of lung cancer, n (%)
5 (39)4 (40)Yes
8 (62)6 (60)No
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Each usability testing session was facilitated by the researcher
and a member of the study design team. The primary purpose
of the usability testing session was to identify any programming
errors or design issues that would prevent a satisfactory user
experience and to curate additional feedback on the overall
program.
Usability testing involved the participant using the program
twice. First, the participant used the program without
interruption. The researcher and study design team member
observed how the participant interacted with the program and
completed an investigator-developed observer checklist (see
Multimedia Appendix 1). The participant was then asked to use
the program a second time and was stopped at key points for
the researcher to ask questions. The assessment included
questions about specific content, messaging, points of potential
confusion, opinions on visual, written, and verbal content, and
flow design. On completion, the participant completed 2
questionnaires: (1) the 10-item System Usability Scale (SUS;
see Multimedia Appendix 2); and (2) the 21-item Acceptability
and Satisfaction Questionnaire (see Multimedia Appendix 3)
[23,24].
Measures
We measured usability with the 10-item SUS. The SUS
comprises 4-point Likert-response option items (1=strongly
disagree, 2=disagree, 3=agree, 4=strongly agree). Participants
rated items across a variety of specific tasks, including ease of
use, consistency of the computer program, perception of how
integrated the program felt during use, and perception of how
well the computer program was able to prepare the user to
discuss lung cancer screening with their clinician. In addition,
open-ended questions were provided to allow participants to
give feedback on negative and positive impressions of the
overall program, as well as specific components. Participants
were also asked to provide an overall letter grade rating for the
program (ranging from A=excellent to F=unacceptable).
We measured acceptability and satisfaction with a 22-item
questionnaire using a 4-point Likert-response option (1=strongly
disagree to 4=strongly agree). In addition to overall satisfaction
with the computer program, items assessed a variety of
acceptability- and satisfaction-related components of the
computer program, such as (1) amount of time to complete, (2)
clarity of the messages, (3) enjoyment with use, (4) content
relatability, and (5) ability to engage the user.
Analysis and Results
All 13 participants viewed LungTalk twice as previously
described. None of the participants experienced any technical
difficulties during testing (eg, interruption of Internet service,
computer program pausing or ending unexpectedly). However,
3 participants had difficulty recognizing the forward arrow
button at the bottom of the screen to advance the program at
the beginning. All 3 recommended that this button either be
highlighted in green or flashing to indicate that the user needs
to click the button to advance the program. Many users also
recommended changing the settings of the program to
autoadvance forward through the material in different sections
to eliminate the need to click a button. We examined usability
with the SUS. Reverse-coded items on the SUS were
transformed for analysis, and total SUS scores ranged from 62.5
to 85 on a 100-point scale with an overall mean of 75.8 (SD
7.9). Total scores on the Acceptability and Satisfaction
Questionnaire ranged from 79.8 to 97.6 on a 100-point scale
with an overall mean of 90.2 (SD 6.3). Slightly more than half
of the participants gave LungTalk an overall A rating (ie,
excellent; n=7, 54%) with the remainder giving LungTalk a B
rating (good; n=6, 46%).
Phase III: Community-Based, Web-Based Pilot
Randomized Controlled Trial
Overview
Following development and usability testing of LungTalk, we
are conducting a pilot randomized controlled trial (RCT) with
the goal of obtaining preliminary effect size data for a future
fully powered RCT. The pilot RCT will estimate the effect sizes
of LungTalk on (1) changes in knowledge, (2) changes in health
beliefs, and (3) participant perceptions of being adequately
prepared to engage in a discussion with their clinician about
lung cancer screening. Since the purpose of LungTalk is to
prepare individuals for the shared decision-making process
about lung cancer screening, the occurrence of a patient-clinician
discussion about lung cancer screening and actual lung cancer
screening completion are not the primary focuses in this initial
study. However, for exploratory purposes, we will estimate the
effect sizes of LungTalk for both.
Data Collection
Based on the overall objective of the pilot study to obtain
preliminary effect size data, we need at least 12 participants per
group to obtain reasonable effect size estimates to design a
larger, well-powered trial [25,26]. To provide for the potential
of attrition, 60 lung cancer screening-eligible participants who
have not been screened for lung cancer have been recruited from
the community using Facebook targeted advertisement [27].
We have randomly assigned participants to 1 of 2 groups after
baseline data collection. The intervention group received
LungTalk, and the enhanced control group received a
nontailored lung screening information sheet compiled using
patient education material from the American Cancer Society
website [28]. Participants were randomly assigned and stratified
by sex to each group. Stratified random assignment will ensure
that the 2 groups are comparable in distribution. We are
collecting data via REDCap (REDCap Consortium) at 3 time
points via telephone: (1) baseline at recruitment, (2) within 1
week of completing the intervention, and (3) 3 months
postintervention. REDCap is a secure Web-based app for
building and managing online surveys and databases. REDCap
provides audit trails for tracking data manipulation and user
activity, as well as automated export procedures for secure data
downloads to common statistical packages [29].
We are administering a baseline survey to collect data on
sociodemographic and health status characteristics, lung cancer
and screening knowledge, health beliefs (perceived risk of lung
cancer, and perceived benefits of, perceived barriers to, and
self-efficacy for lung cancer screening) [18], self-report of
perception of preparation to engage in a patient-clinician
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discussion about lung cancer screening, and stage of adoption
for lung cancer screening. We are measuring stage of adoption
using an algorithm that is theoretically based on the precaution
adoption process model [30]. This model categorizes individuals
into 1 of 7 stages: unaware, aware but unengaged, undecided,
decided not to act, decided to act, action, and maintenance [30].
At the completion of the baseline survey, each participant has
been randomly assigned to either the intervention group or the
enhanced control group. A link to either LungTalk or the lung
screening information sheet was emailed to the participant based
on their random assignment.
We administered a follow-up survey by telephone within 1 week
of intervention completion. The survey included items to assess
lung cancer and screening knowledge, health beliefs (perceived
risk, perceived benefits, perceived barriers, and self-efficacy)
[18], satisfaction with the intervention, self-report of perception
of preparation to engage in a patient-clinician discussion about
lung cancer screening, self-report of the occurrence of a
patient-clinician discussion about lung cancer screening, and
stage of adoption for lung cancer screening [30].
We will administer a second follow-up telephone survey 3
months after completion of the intervention. The 3-month
follow-up survey will include items to assess self-report of the
occurrence of a patient-clinician discussion about lung cancer
screening, clinician recommendation, and stage of adoption for
lung cancer screening [30]. For individuals who self-report
completing lung cancer screening, we will verify the screening
by mailing an authorization form to the participant to be signed
and mailed back to the research office. A trained research
assistant will verify the LDCT scan to screen for lung cancer
using the information and signed authorization form by
contacting the facility to request confirmation.
Analysis
We will compile deidentified data collected via REDCap and
export it into a SAS file (version 9.4; SAS Institute). Data
completeness will be assessed through descriptive analyses.
Means and standard deviations or frequency distributions will
be examined to check for coding errors and out-of-range values.
All variables will be described with summary statistics
appropriate for measurement level. Key analyses will be
descriptive; we will calculate means and standard deviations
and Cohen d effect sizes of study variables by group and for
each study time point. We will calculate 95% CIs for the effect
sizes using the nonparametric bootstrap approach based on 2000
bootstrap replications. For exploratory purposes, we will fit
linear mixed-effects models with smoking status and race as
factors, and a participant-specific random intercept to account
for the association between the observations of the same
participant. We will also evaluate the feasibility of study
procedures. Therefore, we will calculate participation rates and
rates of completion and retention of participants at (1) baseline
survey, (2) 1-week postintervention survey, and (3) 3-month
postintervention survey. For each, we will calculate the
proportion of people who were recruited initially and retained
at each stage, along with the associated 95% CI. Patterns of
missing values will be examined and evaluated for randomness
using the method described by Enders [31]. We will evaluate
diagnostic plots and inferential tests for tenability of assumptions
and apply appropriate remedial methods where required.
For the pilot RCT, we will estimate initial differences between
the 2 intervention groups with respect to key study variables.
We will recruit 30 participants per group to estimate effect sizes
of LungTalk on (1) changes in knowledge, (2) changes in health
beliefs, (3) self-report of participant perceptions of being
adequately prepared to engage in a discussion with their clinician
about lung cancer screening, (4) occurrence of a patient-clinician
discussion about lung cancer screening, and (5) stage of adoption
for lung cancer screening. Key analyses will be descriptive; we
will calculate means and standard deviations of study variables
by group. For exploratory purposes, we will also fit 2-way
analysis of variance models with smoking status and race as
factors.
Results
We are conducting the pilot RCT. Recruitment began on June
15, 2017 using Facebook targeted advertisement. As of July 15,
2017, all 60 participants have been enrolled into the study and
have completed the baseline survey, the intervention, and the
first follow-up survey. We expect to have final results by
December 31, 2017 and to have completed data analysis by
March 1, 2018.
Discussion
Results from pretesting LungTalk in the usability laboratory
indicate that the computer program is easy to use, is helpful,
and provides a satisfactory experience for the user. The pilot
RCT will provide preliminary effect sizes of changes in (1)
knowledge about lung cancer and screening, (2) perceived risk
of lung cancer, (3) perceived benefits of lung cancer screening,
(4) perceived barriers to lung cancer screening, (5) self-efficacy
for lung cancer screening, and (6) participant perceptions of
being adequately prepared to engage in a discussion with their
clinician about lung cancer screening. We anticipate that
LungTalk will be helpful to screening-eligible individuals as a
tool to support those considering the option to screen, or not,
for lung cancer. Specifically, LungTalk can help enhance the
shared decision-making process in lung cancer screening by
priming individuals with essential baseline knowledge for the
discussion and decision-making process.
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